LRRC1: A Unique Protein with Potential Clinical Applications (G55227)

Target Name: LRRC1

NCBI ID: G55227

LRRC1

LRRC1: A Unique Protein with Potential Clinical Applications

LRRC1 (Leucine-rich repeat-containing 1) is a protein that is expressed in various tissues and cells in the human body. It is characterized by the presence of a unique repeat sequence at its C-terminus that is composed of the amino acids leucine, glutamic acid, and cysteine. This repeat sequence is highly conserved across various species, including humans, and is thought to be a key factor in the protein's stability and functions.

One of the unique features of LRRC1 is its ability to interact with other proteins, particularly those that are involved in the regulation of cell signaling pathways. This interaction has led some researchers to consider LRRC1 as a potential drug target or biomarker for a variety of diseases.

The exact function of LRRC1 is not yet fully understood, but it is known to play a role in the regulation of several cellular processes, including cell signaling, DNA replication, and stress response. LRRC1 has been shown to interact with a variety of proteins, including the transcription factor NF-kappa-B and the protein tyrosine kinase BCR.

In addition to its potential drug-targeting properties, LRRC1 has also been identified as a potential biomarker for several diseases. For example, some studies have suggested that LRRC1 may be involved in the development of cancer, particularly breast cancer. This is based on the fact that LRRC1 has been shown to be expressed at higher levels in breast tissue than in other tissues, and that inhibition of LRRC1 has been shown to have anti-tumor effects.

Another potential application of LRRC1 as a biomarker is its role in the diagnosis of neurodegenerative diseases, such as Alzheimer's disease. LRRC1 has been shown to be expressed at higher levels in the brains of individuals with Alzheimer's disease than in those without the disease, and inhibition of LRRC1 has been shown to have potential therapeutic benefits in these conditions.

In addition to its potential clinical applications, LRRC1 has also generated a significant amount of interest among researchers due to its unique structure and function. The repeat sequence at its C-terminus, which is composed of the amino acids leucine, glutamic acid, and cysteine, has been studied extensively in the literature, and its properties have been predicted to be involved in a variety of cellular processes.

For example, the repeat sequence has been shown to be involved in the regulation of protein stability and function, as well as in the regulation of cellular signaling pathways. In addition, LRRC1 has been shown to play a role in the regulation of cell division and apoptosis, as well as in the development of cancer.

Overall, LRRC1 is a protein that has generated a significant amount of interest among researchers due to its unique structure and function. While its exact role in the regulation of cellular processes is not yet fully understood, its potential as a drug target or biomarker for a variety of diseases makes it a promising area of study.

Protein Name: Leucine Rich Repeat Containing 1

The "LRRC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets